Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Rachel Rabinovitch

Concepts (351)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Breast Neoplasms
62
2025
2452
3.810
 Why?
Mastectomy, Segmental
29
2025
108
2.080
 Why?
Hodgkin Disease
9
2026
171
1.650
 Why?
Lymphoma, Large B-Cell, Diffuse
9
2025
192
1.400
 Why?
Brachytherapy
10
2019
134
1.280
 Why?
Carcinoma, Intraductal, Noninfiltrating
8
2025
61
1.280
 Why?
Neoplasm Staging
34
2020
1462
1.060
 Why?
Mastectomy
8
2025
162
1.030
 Why?
Neoplasm Recurrence, Local
14
2025
1137
1.030
 Why?
Mediastinal Neoplasms
3
2017
51
1.030
 Why?
Radiotherapy, Adjuvant
18
2025
222
0.990
 Why?
Radiotherapy, Conformal
7
2016
74
0.900
 Why?
Antineoplastic Combined Chemotherapy Protocols
13
2026
1953
0.870
 Why?
Radiation Pneumonitis
1
2024
31
0.830
 Why?
Combined Modality Therapy
25
2024
1266
0.830
 Why?
Lymphoma, Follicular
4
2023
56
0.750
 Why?
Radiation Oncologists
1
2021
4
0.700
 Why?
Lymphoma, B-Cell
2
2025
132
0.640
 Why?
Carcinoma, Ductal, Breast
10
2016
88
0.570
 Why?
Radiotherapy Planning, Computer-Assisted
6
2020
149
0.530
 Why?
Female
80
2025
78271
0.490
 Why?
Breast
3
2013
158
0.490
 Why?
Middle Aged
54
2026
35875
0.480
 Why?
Mammography
5
2019
166
0.480
 Why?
Medical Oncology
4
2026
332
0.470
 Why?
Humans
110
2026
144759
0.470
 Why?
Cord Blood Stem Cell Transplantation
3
2024
103
0.470
 Why?
SEER Program
7
2019
224
0.460
 Why?
Aged, 80 and over
20
2025
8265
0.450
 Why?
Prognosis
16
2024
4282
0.430
 Why?
Radiotherapy Dosage
13
2025
289
0.420
 Why?
Transplantation Conditioning
5
2024
186
0.420
 Why?
Aged
40
2025
25913
0.410
 Why?
Lymph Nodes
5
2016
502
0.410
 Why?
Breast Neoplasms, Male
1
2013
29
0.400
 Why?
Kaplan-Meier Estimate
6
2020
965
0.400
 Why?
Neoplasms, Second Primary
3
2020
100
0.400
 Why?
Proportional Hazards Models
6
2022
1325
0.400
 Why?
Treatment Outcome
21
2025
11679
0.380
 Why?
BRCA2 Protein
3
2020
67
0.380
 Why?
Adult
46
2026
40449
0.370
 Why?
Radiosurgery
2
2019
400
0.360
 Why?
Radiotherapy
6
2015
206
0.360
 Why?
Prostatic Neoplasms
4
2022
974
0.360
 Why?
Mammaplasty
1
2013
104
0.350
 Why?
Lymphoma, Non-Hodgkin
3
2021
124
0.350
 Why?
Follow-Up Studies
11
2024
5408
0.350
 Why?
Healthcare Disparities
1
2018
727
0.350
 Why?
Delivery of Health Care
1
2018
947
0.350
 Why?
Survival Analysis
9
2018
1382
0.340
 Why?
Lymphoma
2
2025
232
0.310
 Why?
Whole-Body Irradiation
5
2020
76
0.310
 Why?
BRCA1 Protein
2
2020
81
0.310
 Why?
Hematopoietic Stem Cell Transplantation
4
2024
675
0.310
 Why?
Disease-Free Survival
8
2025
769
0.300
 Why?
Anthracyclines
1
2009
47
0.300
 Why?
Radiation Oncology
5
2025
88
0.290
 Why?
Sentinel Lymph Node Biopsy
3
2008
118
0.290
 Why?
Neoplasms, Radiation-Induced
3
2020
99
0.280
 Why?
Antibiotics, Antineoplastic
1
2009
139
0.280
 Why?
Bile Duct Diseases
1
2008
13
0.270
 Why?
Graft vs Host Disease
5
2024
264
0.270
 Why?
Cholestasis, Intrahepatic
1
2008
29
0.270
 Why?
Leukemia, Lymphocytic, Chronic, B-Cell
3
2017
76
0.270
 Why?
Neoplasm Grading
6
2022
307
0.270
 Why?
Bile Ducts, Intrahepatic
1
2008
62
0.260
 Why?
Radiotherapy, Intensity-Modulated
3
2014
141
0.260
 Why?
Thoracic Vertebrae
1
2007
79
0.260
 Why?
Lymphoma, Mantle-Cell
2
2025
32
0.260
 Why?
United States
16
2019
15966
0.240
 Why?
Prostheses and Implants
1
2007
141
0.240
 Why?
Nutritional Support
1
2006
39
0.240
 Why?
Trastuzumab
3
2024
118
0.240
 Why?
Heart Diseases
1
2009
349
0.230
 Why?
Young Adult
10
2026
14105
0.230
 Why?
Orbital Neoplasms
1
2025
27
0.220
 Why?
Receptors, Estrogen
4
2016
457
0.210
 Why?
Survival Rate
8
2019
2089
0.210
 Why?
Transplantation, Haploidentical
1
2024
23
0.210
 Why?
Male
28
2025
72315
0.200
 Why?
Adolescent
12
2026
22428
0.190
 Why?
Time Factors
5
2018
7173
0.190
 Why?
Head and Neck Neoplasms
2
2010
558
0.180
 Why?
Flutamide
2
2018
7
0.180
 Why?
Goserelin
2
2018
8
0.180
 Why?
Analysis of Variance
2
2015
1306
0.180
 Why?
Neoplasm Invasiveness
4
2019
508
0.170
 Why?
Neoadjuvant Therapy
3
2025
462
0.170
 Why?
Patient Care Planning
2
2021
169
0.170
 Why?
Bone Neoplasms
2
2018
253
0.170
 Why?
Cause of Death
2
2016
471
0.170
 Why?
Carcinoma, Squamous Cell
1
2006
641
0.170
 Why?
Survivorship
1
2021
54
0.170
 Why?
Androgen Antagonists
2
2022
91
0.160
 Why?
Deoxycytidine
1
2022
221
0.160
 Why?
Tumor Burden
4
2016
319
0.160
 Why?
Adenocarcinoma
2
2018
928
0.160
 Why?
Azacitidine
1
2021
156
0.160
 Why?
Immunoconjugates
1
2021
132
0.160
 Why?
Surgical Instruments
1
2000
51
0.150
 Why?
Retrospective Studies
12
2025
17066
0.150
 Why?
Clinical Trials as Topic
5
2017
1053
0.150
 Why?
Antineoplastic Agents, Immunological
2
2019
199
0.150
 Why?
Antineoplastic Agents
7
2017
2194
0.150
 Why?
Radiation Injuries
3
2016
151
0.150
 Why?
Antibodies, Monoclonal, Humanized
2
2017
985
0.150
 Why?
Biomarkers, Tumor
2
2024
1313
0.150
 Why?
Vidarabine
3
2018
32
0.140
 Why?
Patient Satisfaction
2
2013
704
0.140
 Why?
Leuprolide
1
2018
21
0.140
 Why?
Aquaporin 4
1
2019
98
0.140
 Why?
Neoplasms
2
2011
2875
0.140
 Why?
Public Health Surveillance
1
2018
83
0.140
 Why?
Thiotepa
1
2018
21
0.140
 Why?
Necrosis
1
2019
244
0.140
 Why?
Diphosphonates
1
2018
68
0.140
 Why?
Rituximab
2
2016
209
0.130
 Why?
Randomized Controlled Trials as Topic
8
2022
1720
0.130
 Why?
Leukemia, Myeloid, Acute
2
2021
682
0.130
 Why?
Patient Care Management
1
2017
56
0.130
 Why?
Disease Management
2
2018
645
0.130
 Why?
Imidazoles
1
2018
254
0.130
 Why?
Chemoradiotherapy
1
2018
237
0.130
 Why?
Aromatase Inhibitors
1
2017
75
0.130
 Why?
Lymphoma, Extranodal NK-T-Cell
1
2016
10
0.130
 Why?
Unilateral Breast Neoplasms
1
2016
4
0.120
 Why?
Practice Guidelines as Topic
4
2017
1560
0.120
 Why?
Multivariate Analysis
3
2009
1539
0.120
 Why?
Lymphoma, T-Cell, Peripheral
1
2016
20
0.120
 Why?
Margins of Excision
1
2016
51
0.120
 Why?
Recurrence
5
2018
1135
0.120
 Why?
Esthetics
2
2013
41
0.120
 Why?
Datasets as Topic
1
2016
122
0.120
 Why?
Chemotherapy, Adjuvant
6
2017
421
0.110
 Why?
Biopsy
5
2022
1075
0.110
 Why?
Programmed Cell Death 1 Receptor
1
2017
264
0.110
 Why?
Gastrointestinal Neoplasms
2
2012
70
0.110
 Why?
Prostate-Specific Antigen
3
2022
161
0.110
 Why?
Risk Reduction Behavior
1
2016
226
0.110
 Why?
Risk Factors
5
2022
10779
0.110
 Why?
Patient Selection
4
2016
719
0.110
 Why?
Carcinoma
1
2016
228
0.110
 Why?
Quality of Life
2
2025
3185
0.110
 Why?
Gene Expression Profiling
3
2017
1782
0.110
 Why?
Insurance Coverage
1
2016
239
0.100
 Why?
Cancer Survivors
1
2019
327
0.100
 Why?
Genetic Predisposition to Disease
2
2020
2363
0.100
 Why?
Antibodies, Monoclonal, Murine-Derived
1
2014
97
0.100
 Why?
Propensity Score
1
2016
367
0.100
 Why?
Societies, Medical
4
2016
887
0.100
 Why?
Immunotherapy, Adoptive
3
2023
337
0.100
 Why?
Beauty
1
2013
19
0.100
 Why?
Receptors, Progesterone
2
2013
356
0.100
 Why?
Lymphatic Irradiation
2
2010
10
0.100
 Why?
Practice Patterns, Physicians'
3
2017
1356
0.100
 Why?
Triple Negative Breast Neoplasms
1
2016
215
0.100
 Why?
Diagnostic Self Evaluation
1
2013
23
0.100
 Why?
Axilla
3
2007
51
0.100
 Why?
Confidence Intervals
1
2013
333
0.100
 Why?
Age Distribution
1
2013
403
0.090
 Why?
Gene Expression Regulation, Neoplastic
1
2019
1455
0.090
 Why?
Prospective Studies
8
2022
7990
0.090
 Why?
Lymphatic Metastasis
4
2019
333
0.090
 Why?
Sex Distribution
1
2013
386
0.090
 Why?
Palliative Care
2
2018
1002
0.090
 Why?
Carcinoma, Renal Cell
1
1994
234
0.080
 Why?
Immunotherapy
1
2016
653
0.080
 Why?
Cyclophosphamide
2
2009
266
0.080
 Why?
Health Physics
1
2010
7
0.080
 Why?
Guideline Adherence
2
2017
589
0.080
 Why?
Immunosuppressive Agents
3
2006
846
0.080
 Why?
Four-Dimensional Computed Tomography
1
2010
38
0.080
 Why?
Lung Neoplasms
2
2018
2637
0.080
 Why?
Boronic Acids
1
2010
37
0.080
 Why?
Antibodies, Monoclonal
1
2017
1519
0.080
 Why?
Clinical Trials, Phase III as Topic
2
2010
117
0.070
 Why?
Kidney Neoplasms
1
1994
412
0.070
 Why?
Doxorubicin
2
2009
397
0.070
 Why?
Pyrazines
1
2010
92
0.070
 Why?
Pregnancy Complications, Neoplastic
1
2009
63
0.070
 Why?
Thrombophilia
1
2009
88
0.070
 Why?
Mutation
1
2020
4089
0.070
 Why?
Databases as Topic
1
2008
71
0.070
 Why?
Iridium Radioisotopes
1
2007
4
0.070
 Why?
Movement
1
2010
293
0.070
 Why?
Diagnostic Imaging
1
2010
338
0.070
 Why?
Positron-Emission Tomography
3
2017
323
0.070
 Why?
Antineoplastic Agents, Hormonal
2
2008
194
0.070
 Why?
Sex Factors
1
2013
2112
0.070
 Why?
Prednisone
1
2008
221
0.060
 Why?
Comorbidity
3
2017
1658
0.060
 Why?
Registries
1
2016
2385
0.060
 Why?
Syndrome
1
2008
380
0.060
 Why?
Fatigue
2
2025
366
0.060
 Why?
Incidence
1
2013
2879
0.060
 Why?
Sternum
1
2006
26
0.060
 Why?
Stomatitis
1
2006
16
0.060
 Why?
Age Factors
2
2017
3333
0.060
 Why?
Radiology
1
2008
174
0.060
 Why?
Carcinoma, Small Cell
1
2006
173
0.060
 Why?
Risk Assessment
2
2025
3671
0.060
 Why?
Conjunctival Neoplasms
1
2025
7
0.060
 Why?
Carcinoma, Ductal
1
2005
10
0.060
 Why?
Mycophenolic Acid
1
2006
120
0.060
 Why?
Lymphoma, B-Cell, Marginal Zone
1
2025
19
0.060
 Why?
Nomograms
1
2025
59
0.050
 Why?
Child
3
2024
22633
0.050
 Why?
Tacrolimus
1
2006
196
0.050
 Why?
Stem Cell Transplantation
1
2006
191
0.050
 Why?
Mastectomy, Modified Radical
2
2000
6
0.050
 Why?
Anemia, Sideroblastic
1
2003
4
0.050
 Why?
Living Donors
1
2006
280
0.050
 Why?
Radiography
2
2010
844
0.050
 Why?
Reproducibility of Results
5
2012
3409
0.050
 Why?
Tomography, X-Ray Computed
3
2009
2730
0.050
 Why?
Drug Administration Schedule
2
2018
779
0.050
 Why?
Drug Resistance, Neoplasm
2
2019
881
0.050
 Why?
Magnetic Resonance Imaging
3
2019
3863
0.050
 Why?
Mass Screening
1
2010
1347
0.040
 Why?
Lymph Node Excision
3
2009
173
0.040
 Why?
Professional Staff Committees
1
2001
10
0.040
 Why?
Referral and Consultation
1
2007
851
0.040
 Why?
Antigens, CD19
1
2021
129
0.040
 Why?
Allografts
1
2021
150
0.040
 Why?
Organ Size
2
2013
463
0.040
 Why?
Weight Loss
1
2006
836
0.040
 Why?
Automation
1
2020
102
0.040
 Why?
Carcinoma, Lobular
1
2000
56
0.040
 Why?
Risk Management
1
2020
84
0.040
 Why?
Quality Assurance, Health Care
2
2012
340
0.040
 Why?
Germ-Line Mutation
1
2020
172
0.040
 Why?
Respiration
2
2010
206
0.040
 Why?
Bridged Bicyclo Compounds, Heterocyclic
1
2021
279
0.040
 Why?
Salvage Therapy
1
2000
162
0.040
 Why?
Kallikreins
1
2018
25
0.040
 Why?
Workflow
1
2020
184
0.040
 Why?
Myeloablative Agonists
1
2018
23
0.030
 Why?
Fetal Blood
1
2020
342
0.030
 Why?
Maximum Tolerated Dose
2
2010
212
0.030
 Why?
Osteoblasts
1
2018
145
0.030
 Why?
Radiopharmaceuticals
1
2018
194
0.030
 Why?
Sulfonamides
1
2021
580
0.030
 Why?
Aftercare
1
2019
223
0.030
 Why?
Neutropenia
2
2010
155
0.030
 Why?
Genomics
1
2022
834
0.030
 Why?
Canada
1
2018
428
0.030
 Why?
Retreatment
1
2017
77
0.030
 Why?
Asparaginase
1
2016
30
0.030
 Why?
Fat Necrosis
1
2016
10
0.030
 Why?
Metaplasia
1
2016
57
0.030
 Why?
Socioeconomic Factors
2
2017
1326
0.030
 Why?
Safety
1
2018
356
0.030
 Why?
Ultrasonography
1
2000
770
0.030
 Why?
North America
1
2016
310
0.030
 Why?
Europe
1
2016
412
0.030
 Why?
Herpesvirus 4, Human
1
2016
176
0.030
 Why?
Survivors
1
2019
520
0.030
 Why?
Heart
2
2010
636
0.030
 Why?
Genetic Variation
1
2020
983
0.030
 Why?
T-Lymphocytes
1
2023
1982
0.030
 Why?
Gene Rearrangement
1
2016
155
0.030
 Why?
Postmenopause
2
2009
391
0.030
 Why?
Immunophenotyping
1
2016
322
0.030
 Why?
DNA, Viral
1
2016
358
0.030
 Why?
Advisory Committees
1
2016
228
0.030
 Why?
Catheterization, Peripheral
1
2016
118
0.030
 Why?
Proto-Oncogene Proteins c-bcl-2
1
2016
240
0.030
 Why?
Radioimmunotherapy
1
2014
22
0.030
 Why?
Proto-Oncogene Proteins c-myc
1
2016
167
0.030
 Why?
Odds Ratio
1
2017
1075
0.030
 Why?
Actuarial Analysis
1
1994
21
0.030
 Why?
Molecular Targeted Therapy
1
2017
432
0.030
 Why?
Clinical Decision-Making
1
2017
359
0.020
 Why?
Treatment Failure
1
1994
365
0.020
 Why?
Child, Preschool
1
2008
11787
0.020
 Why?
Mass Media
1
2012
41
0.020
 Why?
Surveys and Questionnaires
1
2025
6048
0.020
 Why?
Palpation
1
2010
15
0.020
 Why?
Ultrasonography, Mammary
1
2010
15
0.020
 Why?
Anti-Bacterial Agents
1
2001
1907
0.020
 Why?
Logistic Models
1
2016
2117
0.020
 Why?
Urologic Neoplasms
1
2010
31
0.020
 Why?
Thoracic Neoplasms
1
2010
39
0.020
 Why?
Bortezomib
1
2010
55
0.020
 Why?
Lymphopenia
1
2010
65
0.020
 Why?
Subcutaneous Fat
1
2010
78
0.020
 Why?
Brain Neoplasms
1
2019
1318
0.020
 Why?
Nausea
1
2010
111
0.020
 Why?
Soft Tissue Neoplasms
1
2010
127
0.020
 Why?
Pregnancy Trimester, Second
1
2009
82
0.020
 Why?
Statistics, Nonparametric
1
2010
427
0.020
 Why?
Genital Neoplasms, Female
1
2010
99
0.020
 Why?
Radiation Dosage
1
2010
192
0.020
 Why?
Prevalence
1
2016
2834
0.020
 Why?
Infusions, Intravenous
1
2010
423
0.020
 Why?
Pregnancy Trimester, First
1
2009
136
0.020
 Why?
Diarrhea
1
2010
192
0.020
 Why?
Calcinosis
1
2010
234
0.020
 Why?
Apoptosis Regulatory Proteins
1
2009
186
0.020
 Why?
Premenopause
1
2009
123
0.020
 Why?
Longitudinal Studies
1
2016
2947
0.020
 Why?
Observer Variation
1
2009
355
0.020
 Why?
Perimenopause
1
2008
66
0.020
 Why?
Credentialing
1
2007
21
0.020
 Why?
Quality Control
1
2008
163
0.020
 Why?
Fibrosis
1
2010
548
0.020
 Why?
In Situ Hybridization, Fluorescence
1
2008
322
0.020
 Why?
Algorithms
1
2015
1837
0.020
 Why?
Evidence-Based Medicine
1
2010
732
0.020
 Why?
Medicare
1
2012
886
0.020
 Why?
Benchmarking
1
2007
188
0.020
 Why?
Diagnosis, Differential
1
2010
1489
0.020
 Why?
Lung
2
2010
4109
0.010
 Why?
Taxoids
1
2006
116
0.010
 Why?
Etoposide
1
2006
166
0.010
 Why?
Carboplatin
1
2006
160
0.010
 Why?
Signal Transduction
1
2019
5226
0.010
 Why?
Dose-Response Relationship, Drug
1
2010
2027
0.010
 Why?
Genital Diseases, Male
1
1985
17
0.010
 Why?
Colorado
2
2010
4564
0.010
 Why?
Genital Diseases, Female
1
1985
31
0.010
 Why?
Biomarkers
1
2016
4271
0.010
 Why?
Chlamydia trachomatis
1
1985
49
0.010
 Why?
Siblings
1
2006
195
0.010
 Why?
Pharynx
1
1985
59
0.010
 Why?
Immunohistochemistry
1
2008
1716
0.010
 Why?
Neoplasm Proteins
1
2007
442
0.010
 Why?
Cisplatin
1
2006
334
0.010
 Why?
Rectum
1
1985
180
0.010
 Why?
Hematologic Neoplasms
1
2006
161
0.010
 Why?
Antilymphocyte Serum
1
2003
61
0.010
 Why?
Feasibility Studies
1
2007
1095
0.010
 Why?
Sexually Transmitted Diseases
1
1985
166
0.010
 Why?
Fatal Outcome
1
2003
307
0.010
 Why?
Graft Rejection
1
2006
540
0.010
 Why?
Transplantation, Homologous
1
2003
415
0.010
 Why?
Skin Neoplasms
1
2009
847
0.010
 Why?
Transplantation, Heterologous
1
2001
193
0.010
 Why?
Organizational Objectives
1
2001
66
0.010
 Why?
Hospitals, Private
1
1999
12
0.010
 Why?
Hospitals, County
1
1999
11
0.010
 Why?
Hospitals, University
1
1999
176
0.010
 Why?
Forecasting
1
2001
391
0.010
 Why?
Infant, Newborn
1
2009
6429
0.010
 Why?
Reoperation
1
2000
630
0.010
 Why?
Pregnancy
1
2009
7190
0.010
 Why?
Patient Education as Topic
1
1999
780
0.010
 Why?
Bacteriological Techniques
1
1985
68
0.000
 Why?
Chlamydia Infections
1
1985
81
0.000
 Why?
Risk
1
1985
911
0.000
 Why?
Sexual Behavior
1
1985
491
0.000
 Why?
Rabinovitch's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (351) concept(s)
_
Co-Authors Expand Description
See all (42) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)